Derek Whitmill
Family · Idaho Falls, IDNPI 1962919662
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 32.3% of the total. 2025 is the largest year on record at $1,252, 2.1 times the $600 reported in 2021. Among family clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$541
- Novo Nordisk$370
- GSK$318
- AstraZeneca$315
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$176
- plus $1K from 32 others
What the payments were for
- Food & beverage$4,718100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,736 in reported general payments places this provider in the 90th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 150 | $151,582 |
| OzempicSemaglutide | 157 | $146,804 |
| MounjaroTirzepatide | 104 | $110,833 |
| EliquisApixaban | 89 | $63,996 |
| JardianceEmpagliflozin | 60 | $48,077 |
| RybelsusSemaglutide | 21 | $41,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $32,587 |
| LinzessLinaclotide | 35 | $26,977 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $19,838 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $19,730 |
| VraylarCariprazine Hcl | 14 | $19,395 |
| MyrbetriqMirabegron | 27 | $18,898 |
| DapagliflozinDapagliflozin Propanediol | 25 | $17,105 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $16,506 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $15,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $370 | $188,381178 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $315 | $171,420175 claims |
| Lilly USA, LLCMounjaro, Trulicity | $106 | $122,981117 claims |
| AbbVieLinzess, Vraylar, Qulipta, Ubrelvy | $1,529 | $71,41474 claims |
| PfizerEliquis | $137 | $63,99689 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $318 | $55,90096 claims |
| Boehringer IngelheimJardiance | $125 | $48,07760 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $18,89827 claims |
| Johnson & JohnsonXarelto | $38 | $14,79911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Idaho.
Other family in Idaho Falls
- Amber MasseIdaho Falls$17K
- Samantha de Bruyn KopsIdaho Falls$10K
- Paula SanderlinIdaho Falls$10K
- Sunita SigdelIdaho Falls$9K
- Melissa KellyIdaho Falls$7K
- Kelsi RoundsIdaho Falls$6K
- Daniel HuntingIdaho Falls$6K
- Sunny RaichartIdaho Falls$5K
- Malinda McReaIdaho Falls$5K
- Jonathan WilliamsIdaho Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.